Core Viewpoint - The report highlights the performance of the China Europe Medical Health Mixed Fund, managed by Ge Lan and Zhao Lei, indicating a decline in total fund size and negative returns compared to benchmarks for the fourth quarter of 2025 [1][4]. Fund Performance - As of December 31, 2025, the total size of funds managed by Ge Lan decreased from 43.544 billion to 35.389 billion yuan [1]. - The net value growth rate for Class A shares of the China Europe Medical Health Mixed Fund was -14.81%, while the benchmark return was -8.21% [1]. - Class C shares experienced a net value growth rate of -14.98%, also underperforming the benchmark [1]. Holdings Overview - The top ten holdings of the China Europe Medical Health Mixed Fund include WuXi AppTec, Heng Rui Medicine, and Kanglong Chemical, with notable increases in holdings for Hai Si Ke and Tai Ge Medicine, while reductions were seen in stocks like Ke Lun Pharmaceutical and Xin Li Tai [1][2]. - The largest holding, WuXi AppTec, accounted for 10.11% of the fund's net value, with a market value of approximately 2.724 billion yuan [2]. Market Context - The CSI Medical Index fell by 12.7% in the fourth quarter of 2025, underperforming the Shanghai and Shenzhen 300 Index, which declined by only 0.2% [3]. - There was significant differentiation within sub-sectors, with the innovative industry chain entering a correction phase after previous gains, while traditional Chinese medicine and pharmaceutical commerce showed relative stability [3]. Future Outlook - Looking ahead to the first quarter of 2026, improvements in global liquidity are expected to boost investment and financing in innovative drugs, supported by domestic policy enhancements [4]. - The innovative drug and medical device industry chain is anticipated to maintain high levels of activity, with several key domestic drugs approaching critical data readout points [5]. - The CXO sector is expected to benefit from a recovery in biotechnology financing, leading to improved order conditions [5]. - The pharmaceutical sector is projected to experience structural trends driven by macroeconomic improvements, supportive industry policies, and ongoing innovation [5].

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. has successfully issued its first phase of technology innovation bonds for 2026, raising funds for debt repayment and working capital [1][2]. Group 1 - The company received approval from the board of directors and shareholders for the issuance of non-financial corporate debt financing tools on April 22, 2025, and May 19, 2025, respectively [1]. - The company was granted a registration notice by the China Interbank Market Dealers Association on September 16, 2025, allowing for a medium-term note registration quota of RMB 3 billion, valid for two years [2]. - The first phase of the technology innovation bonds was issued on January 19, 2026, with the total funds raised credited to the company on January 20, 2026 [2]. Group 2 - The funds raised from this bond issuance will be used to repay existing debts and supplement working capital [2]. - As of the date of the announcement, the company is not classified as a dishonest entity [2].

2026年度第一期科技创新债券发行结果的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"）《关于公司发行非金融 企业债务融资工具的议案》已于2025年4月22日经公司第八届董事会第六次会议 审议通过，并于2025年5月19日经公司2024年年度股东大会审议批准。相关董事 会和股东大会决议公告详见2025年4月24日和2025年5月20日的《证券时报》、 《上海证券报》、《证券日报》和《中国证券报》以及公司指定信息披露网站 巨潮资讯网（http://www.cninfo.com.cn）。 公司于2025年9月18日收到中国银行间市场交易商协会（以下简称"交易商 协会"）于2025年9月16日下发的《接受注册通知书》（以下简称《通知书》） （中市协注〔2025〕MTN904号），交易商协会同意接受公司中期票据注册， 中期票据注册额度为人民币30亿元，注册额度自《通知书》落款之日起2年内有 效。 公司于近日获悉，公司2026年度第一期科技创新债券于2026年1月19日发行， 募集资金已于2026年1月20日全额到账。 证券 ...

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Group 1 - The company has reported that it is currently selling its ergotamine products through various platforms, including WeChat Mini Programs, Tmall, and JD.com [2] - The company has developed a strategic plan for the health and wellness sector and is making steady progress in its implementation [2]

Group 1 - The company has started selling its ergotamine series products through various platforms including WeChat Mini Program, Tmall, and JD.com [1] - The company has developed a corresponding plan for the development of the health sector and is currently making steady progress [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

Summary of Sichuan Kelun Pharmaceutical FY Conference Company Overview - **Company Name**: Kelun-Biotech - **Industry**: Biopharmaceuticals - **Focus Areas**: Oncology, immunology, metabolism, and other therapeutic areas - **Shareholders**: Kelun Pharmaceutical (largest), MSD (second largest and major collaborator) [2][3] Pipeline and Product Development - **Pipeline Programs**: Over 30 programs, including: - 4 approved products with 7 indications - 2 products at NDA stage - Over 10 programs in clinical development - **Employee Count**: Approximately 2,000, with 900 in R&D, 500 in manufacturing and quality control, and 500 in sales and marketing [3][4] - **Key Products**: - TROP2 ADC (sac-TMT): Approved for three indications in China, including lung cancer and breast cancer - HER2-ADC (trastuzumab botidotec): Approved for HER2-positive breast cancer - Cetuximab: Approved for RAS wild-type colorectal cancer - PD-L1 for nasopharyngeal carcinoma (NPC) [4][5][11] Clinical Studies and Approvals - **Clinical Studies**: Initiated five pivotal studies for breast cancer, six for lung cancer, and one for gastrointestinal cancer [5] - **Expected Approvals**: Anticipation of more product approvals and label expansions in 2026, including a small molecule RET inhibitor [3][6] - **Global Studies**: MSD is initiating 16 global phase three studies for various cancers [9] Market Position and Strategy - **National Reimbursement Drug List (NRDL)**: Three core products included in NRDL 2025, effective January 2026 [7] - **Commercialization Strategy**: Full-fledged commercialization team established with access to Class III hospitals and key opinion leaders [6] - **Partnerships**: Collaborations with MSD, Ellipses, Wonderworld Bio, and Keratin Bio to enhance pipeline value and global market reach [7][8] Innovation and Future Plans - **OptiDC Platform**: Focus on optimized drug conjugate technology, with plans to expand into non-oncology areas [12][15] - **Research Focus**: Development of novel payloads, linkers, and ADC designs, including bispecific antibodies and non-toxin-based drug conjugates [14][15] - **Growth Plans**: Prioritizing differentiated pipeline programs, expanding drug development and commercialization capabilities, and enhancing global partnerships [15][16] Key Performance Metrics - **Efficacy Data**: - TROP2 ADC demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) in clinical trials [10] - HER2-ADC showed improved PFS and overall response rate (ORR) compared to T-DM1 [11] This summary encapsulates the key points from the conference, highlighting the company's strategic focus, product pipeline, clinical advancements, and future growth plans.

Core Viewpoint - The report highlights the growth trends in China's chemical pharmaceutical raw materials industry, indicating a steady increase in production and market dynamics from 2025 to 2032 [1] Industry Summary - In November 2025, China's chemical pharmaceutical raw material production reached 331,000 tons, reflecting a year-on-year growth of 1.5% [1] - From January to November 2025, the cumulative production of chemical pharmaceutical raw materials in China was 3,358,000 tons, with a cumulative growth of 1.8% [1] - The report by Zhiyan Consulting provides insights into the supply and demand dynamics of the chemical pharmaceutical industry in China, projecting future trends from 2026 to 2032 [1] Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1]

Group 1 - The core viewpoint of the news is that Kelun Pharmaceutical has experienced a continuous increase in stock price, rising for seven consecutive days with a cumulative increase of 17.86% [1] - As of the report, Kelun Pharmaceutical's stock price is 33.98 yuan per share, with a total market capitalization of 54.302 billion yuan and a trading volume of 876 million yuan [1] - The company's main business involves the development, production, and sales of large-volume infusion products, with revenue composition being 48.37% from non-infusion products, 41.28% from infusion products, 7.01% from research projects, and 3.33% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Shenwan Hongyuan has a significant position in Kelun Pharmaceutical, with a holding of 106,000 shares, representing 1.56% of the fund's net value [2] - The fund, Shenwan Hongyuan CSI Pharmaceutical Bio Index A, has seen a floating profit of approximately 54,620 yuan during the seven-day stock price increase [2] - The fund has a total asset size of 2.22 billion yuan, with a year-to-date return of 6.59% and a one-year return of 20.61% [2]